World IBD Day 2026

IBD HAS NO BORDERS!

Life with IBD shouldn’t depend on where you live!¹

Inflammatory Bowel Disease (IBD) is a growing global health challenge affecting millions of people worldwide, with increasing prevalence across all age groups, including children and adolescents.²

IBD encompassing Crohn’s disease and ulcerative colitis, remains a major clinical challenge owing to its complex pathophysiology and clinical management as a progressive, chronic disease with many patients relapsing and not achieving optimal disease control.³

From infancy through adulthood, individuals worldwide are affected by inflammatory bowel disease (IBD). Although the precise etiology remains unknown, established environmental risk factors — including pollution exposure, antibiotic use, smoking status*, obesity, and pro-inflammatory dietary patterns — are recognized determinants contributing to the rising prevalence and incidence of IBD in the general population.⁴

In Romania, there are data indicating a trend of increasing incidence in the period 2006–2017 (prospective study), highlighting the need for monitoring and patient registries.⁵

To reduce the burden of IBD, this year’s focus is on increasing access to IBD care by^1,6:

– enabling faster, standardized diagnosis through defined clinical care pathways and rapid referral processes;
– early effective intervention to prevent long-term irreversible bowel damage;
– personalized clinical approach
– primary prevention
– multidisciplinary care
– patients registries

Abbreviations:
IBD, inflammatory bowel disease;
Disclaimer:
*depending on disease: Crohn’s disease/ulcerative colitis
This document has been developed for healthcare professionals as non promotional scientific newsletter

References:
1. IFCCA | The International Federation of Crohn’s & Ulcerative Colitis Associations (IFCCA)
2. G. Ruan et al. Gastroenterology Report, 2025, 13, goaf082 https://doi.org/10.1093/gastro/goaf082
3. Solitano V, et al Nature Reviews Gastroenterology & Hepatology | Volume 22 | June 2025 |438–452
4. Chhibba T, …Kaplan GG. Journal of Crohn’s and Colitis, 2025, 19(4), jjaf042 https://doi.org/10.1093/ecco-jcc/jjaf042
5. Goldis A., Lupusoru R., Gheorghe L., Gheorghe C., Trifan A., Dobru D., Cijevschi C., Tantau A., Constantinescu G., Iacob R, Goldis R., Diculescu M. et al. Medicina 2019, 55, 704; doi:10.3390/medicina55100704
6. Ananthakrishnan AN, Kaplan GG, Ng SC. Clinical Gastroenterology and Hepatology 2020;18:1252–1260

For additional medical information you can use the address: medinfoemea@takeda.com.
Healthcare professionals are asked to report any suspected adverse reactions to Takeda Pharmaceuticals SRL at the email address: AE.ROU@takeda.com or to the Agency National Agency of Medicines and Medical Devices of Romania, Str. Aviator Sănătescu nr. 48, sector 1, Bucharest 011478-RO, e-mail: adr@anm.ro, website: www.anm.ro

If you no longer wish to receive these messages, please unsubscribe here.

Copyright © 2026 Takeda Pharmaceutical Company Limited. All rights reserved.
Takeda and the Takeda Logo are trademarks of Takeda Pharmaceutical Company Limited, used under license.